Global Oral Vaccine for Human Market Growth 2025-2031
Description
The global Oral Vaccine for Human market size is predicted to grow from US$ 2908 million in 2025 to US$ 4098 million in 2031; it is expected to grow at a CAGR of 5.9% from 2025 to 2031.
Orally administered vaccines are of interest, as they elicit both systemic and mucosal immunities, in which mucosal immunity would neutralize the mucosa invading pathogen before the onset of an infection.
The oral vaccine market is driven by the growing demand for convenient and needle-free vaccination options, especially in pediatric and developing regions. Oral vaccines offer advantages like ease of administration, increased patient compliance, and simplified logistics, making them suitable for mass vaccination programs and reaching remote areas with limited healthcare infrastructure. The potential for improved vaccine stability and reduced production costs further contribute to market growth. However, the market also faces challenges, such as the need for enhanced vaccine stability to withstand gastrointestinal conditions and ensuring consistent efficacy across diverse populations. Additionally, regulatory complexities and the requirement for stringent safety and efficacy data can pose obstacles for oral vaccine manufacturers. To succeed in this market, companies must focus on innovative vaccine delivery technologies, conduct robust clinical trials, collaborate with global health agencies, and address public perception and trust in oral vaccine safety and effectiveness.
LP Information, Inc. (LPI) ' newest research report, the “Oral Vaccine for Human Industry Forecast” looks at past sales and reviews total world Oral Vaccine for Human sales in 2024, providing a comprehensive analysis by region and market sector of projected Oral Vaccine for Human sales for 2025 through 2031. With Oral Vaccine for Human sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oral Vaccine for Human industry.
This Insight Report provides a comprehensive analysis of the global Oral Vaccine for Human landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Oral Vaccine for Human portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oral Vaccine for Human market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oral Vaccine for Human and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oral Vaccine for Human.
This report presents a comprehensive overview, market shares, and growth opportunities of Oral Vaccine for Human market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Rotavirus Vaccine
Cholera Vaccine
Oral Polio Vaccine
Other
Segmentation by Application:
Public
Private
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Merck
GSK
Sanofi
Lanzhou Institute
Serum Institute
Valneva
Shanghai United Cell
Bibcol
PaxVax
Vabiotech
Tiantan Biological
EuBiologics
Panacea Biotec Ltd
Bio-Med
Halfkin Bio-Pharmaceuticals
Key Questions Addressed in this Report
What is the 10-year outlook for the global Oral Vaccine for Human market?
What factors are driving Oral Vaccine for Human market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Oral Vaccine for Human market opportunities vary by end market size?
How does Oral Vaccine for Human break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Orally administered vaccines are of interest, as they elicit both systemic and mucosal immunities, in which mucosal immunity would neutralize the mucosa invading pathogen before the onset of an infection.
The oral vaccine market is driven by the growing demand for convenient and needle-free vaccination options, especially in pediatric and developing regions. Oral vaccines offer advantages like ease of administration, increased patient compliance, and simplified logistics, making them suitable for mass vaccination programs and reaching remote areas with limited healthcare infrastructure. The potential for improved vaccine stability and reduced production costs further contribute to market growth. However, the market also faces challenges, such as the need for enhanced vaccine stability to withstand gastrointestinal conditions and ensuring consistent efficacy across diverse populations. Additionally, regulatory complexities and the requirement for stringent safety and efficacy data can pose obstacles for oral vaccine manufacturers. To succeed in this market, companies must focus on innovative vaccine delivery technologies, conduct robust clinical trials, collaborate with global health agencies, and address public perception and trust in oral vaccine safety and effectiveness.
LP Information, Inc. (LPI) ' newest research report, the “Oral Vaccine for Human Industry Forecast” looks at past sales and reviews total world Oral Vaccine for Human sales in 2024, providing a comprehensive analysis by region and market sector of projected Oral Vaccine for Human sales for 2025 through 2031. With Oral Vaccine for Human sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oral Vaccine for Human industry.
This Insight Report provides a comprehensive analysis of the global Oral Vaccine for Human landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Oral Vaccine for Human portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oral Vaccine for Human market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oral Vaccine for Human and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oral Vaccine for Human.
This report presents a comprehensive overview, market shares, and growth opportunities of Oral Vaccine for Human market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Rotavirus Vaccine
Cholera Vaccine
Oral Polio Vaccine
Other
Segmentation by Application:
Public
Private
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Merck
GSK
Sanofi
Lanzhou Institute
Serum Institute
Valneva
Shanghai United Cell
Bibcol
PaxVax
Vabiotech
Tiantan Biological
EuBiologics
Panacea Biotec Ltd
Bio-Med
Halfkin Bio-Pharmaceuticals
Key Questions Addressed in this Report
What is the 10-year outlook for the global Oral Vaccine for Human market?
What factors are driving Oral Vaccine for Human market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Oral Vaccine for Human market opportunities vary by end market size?
How does Oral Vaccine for Human break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
120 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Oral Vaccine for Human by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Oral Vaccine for Human by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
